Millipore and UMass Lowell Dedicate the Millipore Process Development Laboratory
News Apr 10, 2009
Millipore Corporation has announced the opening of the Millipore Corporation Process Development Laboratory in partnership with the University of Massachusetts (UMass) Lowell.
Jean-Paul Mangeolle, President of Millipore’s Bioprocess Division and University of Massachusetts Lowell’s Chancellor Marty Meehan attended the dedication. A number of organizations were also on hand to mark the event and to support the Massachusetts BioManufacturing Center at UMass Lowell.
“This UMass Lowell–Millipore partnership is the perfect example of the value both institutions bring to the regional economy,” said Meehan. “Millipore’s donation will allow us to train our students on state-of-the-art equipment they will use in their future–or current–jobs. Together, UMass Lowell and Millipore are helping to grow the life sciences workforce.”
Millipore donated over $225,000 in equipment and services to the laboratory, which will be used for downstream purification research as well as training for students and industry professionals. The equipment includes clarification, chromatography, ultrafiltration/diafiltration (UF/DF) systems, and disposable mixing systems.
“Millipore strives to be at the forefront of innovation,” said Jean-Paul Mangeolle, President of Millipore’s Bioprocess Division. “Given the dynamic nature of our industry, access to cutting-edge technology and solutions is critical. By partnering with higher education institutions such as UMass Lowell, we further our own knowledge while supporting the local community and helping to educate students who will one day enter the workforce.”
The Millipore Corporation Process Development Laboratory is adjacent to, and works in tandem with, the recently outfitted IPS-Wyeth-Dakota Systems BioManufacturing Pilot Plant. Both are part of the Massachusetts BioManufacturing Center at UMass Lowell, an interdisciplinary research, development and education initiative supported by the University of Massachusetts and the Commonwealth.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019